Menu Search
Equities

TrivarX Ltd

MDBIF:PKC

TrivarX Ltd

Actions
  • Price (USD)0.015
  • Today's Change0.00 / 0.00%
  • Shares traded1.08k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Jun 17 2024 14:30 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

TrivarX Limited, formerly Medibio Limited, is an Australia-based mental health technology company engaged in the use of objective measures to aid in the early detection and screening of mental health conditions. Through the Company’s corporate health product, it offers mental well-being solutions for businesses and is also developing products to serve the healthcare provider market. The principal activity of the Company is conducting clinical research, product development and early-stage commercialization of a mental health technology using objective biomarkers to assist in the screening, diagnosing, monitoring, and management of depression and other mental health conditions. It has launched its consumer mobile application to help measure, monitor, and manage stress, called LUCA. LUCA is a biometric assessment tool that measures sleep stress, activity stress, and cardiac stress that allows consumers to monitor their daily stress levels through their own personal wearable device.

  • Revenue in AUD (TTM)20.81k
  • Net income in AUD-3.74m
  • Incorporated1987
  • Employees4.00
  • Location
    TrivarX LtdLevel 4, 100 Albert RoadSOUTH MELBOURNE 3205AustraliaAUS
  • Phone+61 86189-1155
  • Fax+61 39077-9233
  • Websitehttps://medibio.com.au/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.